Selected publications
-
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
European Urology.
2016
Academic Article
GET IT
Times cited: 25 -
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial.
The lancet oncology.
2013
Academic Article
GET IT
Times cited: 356 -
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial.
Lancet.
2011
Academic Article
GET IT
Times cited: 1052 -
Response: Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Journal of the National Cancer Institute.
2011
Information Resource
GET IT
Times cited: 3 -
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Science Translational Medicine.
2011
Academic Article
GET IT
Times cited: 30 -
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Journal of the National Cancer Institute.
2011
Academic Article
GET IT
Times cited: 371 -
Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials.
Gynecologic Oncology.
2007
Academic Article
GET IT
Times cited: 24 -
Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.
Journal of Clinical Oncology.
1999
Academic Article
GET IT
Times cited: 103